OptimizeRx Reports First Quarter 2025 Financial Results and Updates Fiscal Year 2025 Guidance

Core Insights - OptimizeRx Corp reported strong financial performance for Q1 2025, with revenue increasing by 11% year-over-year to $21.9 million, and gross profit rising by 9% to $13.3 million [7][8] - The company has raised its full-year revenue guidance to a range of $101 million to $106 million, with adjusted EBITDA expected between $13 million and $15 million [5][6][7] Financial Performance - Q1 2025 net revenue was $21.9 million, compared to $19.7 million in Q1 2024, marking an 11% increase [8] - Gross profit for Q1 2025 was $13.3 million, up from $12.2 million in the same period last year, reflecting a 9% increase [8] - The company reported a GAAP net loss of $(2.2) million or $(0.12) per share for Q1 2025, an improvement from a net loss of $(6.9) million or $(0.38) per share in Q1 2024 [8][22] Key Performance Indicators - Average revenue per top 20 pharmaceutical manufacturer increased to $2.96 million in 2025 from $2.59 million in 2024 [5] - The percentage of total revenue attributable to the top 20 pharmaceutical manufacturers decreased slightly to 63% in 2025 from 66% in 2024 [5] - Net revenue retention stood at 114% in 2025, down from 116% in 2024 [5] Strategic Outlook - The company has converted over 5% of its expected 2025 sales into subscription-based revenue streams, indicating a shift towards more stable revenue models [4] - CEO Stephen L. Silvestro expressed confidence in achieving "Rule of 40" performance in the coming years, driven by operational excellence and customer satisfaction [3][4]